Everything You Need to Know: Pfizer, Bristol-Myers Squibb, VIVUS, Sarepta, and St. Jude

In this video, Motley Fool health-care analyst David Williamson talks about some of the biggest investing stories in the health-care space today. He tells us about Pfizer (NYS: PFE) and Bristol-Myers Squibb's (NYS: BMY) latest European victory, a major insurance win for obesity-drug maker VIVUS (NAS: VVUS) , a huge vote of share-price confidence for Sarepta (NAS: SRPT) and its drug for Duchenne muscular dystrophy, and a big tumble for St. Jude Medical (NYS: STJ) after another problem with one of its products.

The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies is looking to change everything. Newly approved drugs, including one developed by VIVUS, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense, but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand-new premium research service. It's such an important story that we have our top health-care writer on the job, so make sure to secure a copy today by clicking here now.

The article Everything You Need to Know: Pfizer, Bristol-Myers Squibb, VIVUS, Sarepta, and St. Jude originally appeared on Fool.com.

Brenton Flynn owns shares of Sarepta Therapeutics. David Williamson owns shares of Pfizer. The Motley Fool owns shares of St. Jude Medical. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.